PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
Top Cited Papers
- 1 March 2015
- journal article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (3), 284-292
- https://doi.org/10.1016/s1470-2045(15)70013-6
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's LymphomaJournal of Clinical Oncology, 2012
- Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapyHaematologica, 2012
- Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell TransplantationTransplantation and Cellular Therapy, 2011
- Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphomaLeukemia & Lymphoma, 2011
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive LymphomasThe New England Journal of Medicine, 2010
- High‐dose chemo‐radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre‐transplant functional imagingBritish Journal of Haematology, 2010
- Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphomaBritish Journal of Haematology, 2009
- Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphomaCancer, 2007
- Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphomaHaematologica, 2007
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993